Home › Calculator › ADCT Dividend Calculator 2026
ADCT Dividend DRIP Calculator 2026
168.07% YieldHealthcareADC Therapeutics S.A. · NYSE
Price: $1.19 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When ADCT pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your ADCT snowball 📈
$10,000 in ADCT → $191.62M in 10 years · $10,011,410.82/month
About ADC Therapeutics S.A. (ADCT) — Dividend Analysis 2026
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL. It is additionally progressing through Phase II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Furthermore, ADC Therapeutics is advancing ADCT-602, currently in Phase Ia for acute lymphoblastic leukemia, alongside ADCT-601 and ADCT-901, both of which are in Phase Ia for various solid tumors. Its preclinical portfolio features ADCT-701 and ADCT-901, both aimed at solid tumors. The company maintains strategic collaboration and license agreements with entities such as Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. Founded in 2011, ADC Therapeutics S.A. has its headquarters located in Epalinges, Switzerland.
Compare ADCT with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full ADCT DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ADCT position with:
🌍 ADCT Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold ADCT.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 168.07% | 165.27% | $16,807 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 142.86% | 140.06% | $14,286 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 134.46% | 131.66% | $13,446 / yr |
| 🇬🇧 UK ISA | 0% | 168.07% | 165.27% | $16,807 / yr |
| 🇬🇧 UK Taxable | 8.75% | 153.36% | 150.56% | $15,336 / yr |
| 🇨🇦 TFSA | 0% | 168.07% | 165.27% | $16,807 / yr |
| 🇨🇦 CA Taxable | 25% | 126.05% | 123.25% | $12,605 / yr |
| 🇦🇺 Super (pension) | 15% | 142.86% | 140.06% | $14,286 / yr |
| 🇦🇺 AU Taxable | 30% | 117.65% | 114.85% | $11,765 / yr |
| 🇩🇪 DE Taxable | 26.375% | 123.74% | 120.94% | $12,374 / yr |
| 🇫🇷 FR Taxable | 30% | 117.65% | 114.85% | $11,765 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 ADCT Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 ADCT Dividend Payment Schedule
ADCT pays quarterly — 4 times per year. Next ex-div: TBD.
📊 ADCT vs Healthcare Benchmarks
How ADCT compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ADCT sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ ADCT Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-06-30 | 213,900 | — | — | ||
| A-Award | 2026-06-30 | 221,100 | — | — | ||
| A-Award | 2026-06-30 | 203,700 | — | — | ||
| A-Award | 2026-06-30 | 675,000 | — | — | ||
| Sale | 2026-03-31 | 196,229 | $3.75 | $736.3K | ||
| Sale | 2026-04-01 | 169,265 | $3.80 | $643.0K | ||
| Sale | 2026-03-31 | 188,407 | $3.75 | $706.9K | ||
| Sale | 2026-04-01 | 162,517 | $3.80 | $617.4K | ||
| Sale | 2026-04-02 | 2,634,506 | $3.28 | $8.64M | ||
| Sale | 2026-04-02 | 2,529,491 | $3.28 | $8.29M |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where ADCT earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ADCT dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
ADC Therapeutics S.A. (ADCT) is currently trading at $1.19, 96% below its 52-week high. The current dividend yield is 168.07% based on an annual payout of $2.00 per share.
ADCT (ADC Therapeutics S.A.) — 168.07% Dividend Yield Analysis
ADC Therapeutics S.A. (ADCT) is a healthcare stock currently trading at $1.19 with a dividend yield of 168.07%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (168.07%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest ADCT News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.